Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Transplant Rejection Clinical Trials

A listing of Transplant Rejection medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (83) clinical trials

The goal of the OPTIMAL study is to gradually reduce anti-rejection medication(s) in liver transplant recipients over a period of time until the medication(s) are stopped. This is called immunosuppression withdrawal. As part of the OPTIMAL study, investigators will also do blood and liver biopsy tests to see whether they ...

Phase N/A

What is the SOLSTICE study? The SOLSTICE study is a clinical research study designed to explore an investigational drug-maribavir-in stem cell transplant and solid organ transplant recipients whose CMV infections are not responding to current treatments. This investigational drug is given as an oral pill. The main goal of the ...

Human Microbiota and Liver Transplant

The microbiota represents the collections of microbial communities that colonize a host. In health, the microbiota protects against pathogens and maturation of the immune system. In return, the immune system determines the composition of the microbiota. Altered microbial composition (dysbiosis) has been correlated with a number of diseases in humans. ...

Phase N/A

Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange

Each year in the Renal Nephrology and Transplantation Department of Grenoble Hospital treat about twenty renal transplant patients with chronic active antibody rejection. Some patients are diagnosed at a very advanced stage and will not be treated because the expected benefit is tenuous (exclusion criteria). For both groups, patients will ...

Phase N/A

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

Median survival after pediatric heart transplantation (HT) is 15 years in the current era. This means that a substantial fraction of patients transplanted during childhood fail to survive to adulthood, or require heart re-transplantation, because of complications related to heart transplant. These complications include heart transplant rejection, infection, coronary artery ...

Phase

Identification of Donor Specific B Cells and Antibody Mediated Rejection

Patients that are sensitized, who have panel reactive antibodies (PRAs) > 20%, comprise a disproportionate and increasing cluster on the wait list (33%), and have to wait longer to receive a transplant than non-sensitized patients. By 36 months on the wait list, 10% died before receiving a transplant. Those who ...

Phase N/A

Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

Subjects will receive Acthar 40 units twice a week subcutaneously for 2 weeks. If the drug is well tolerated the dose will be increased to 80 units twice a week for another 22 weeks. The patients will be maintained on their center-specific standard maintenance regimen, typically consisting of Tacrolimus, mycephenolate ...

Phase N/A

Dose Adjustment of Tacrolimus Based on Home Sampling in Renal Transplant Recipients

Renal transplant recipients using Prograf as part of their immunosuppressive regimen will be included in the study. Patients will receive oral and written study information and sign the informed consent before entering the study. A 12-hour pharmacokinetic investigation will be performed when Tac doses have been stable for at least ...

Phase N/A

An US Mathematical Model in Predicting Renal Transplant Rejection

There are various reasons for renal failure after kidney transplantation, such as delayed graft function (DGF) and acute rejection, acute renal tubular necrosis, chronic rejection and toxicity of immunosuppressive drugs. The diagnosis of renal allografts dysfunction can determine the direction of therapy. Currently, the gold standard of diagnosing renal allografts ...

Phase N/A

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

This is a single-center sample study. A total number of 250 subjects will be consented and enrolled at Northwestern University Transplant clinic at the time of kidney biopsy. At our clinic, protocol biopsy may be performed at 3 months, 12 months , 24 months or any other time the doctor ...

Phase N/A